| Bioactivity | AChE-IN-9 is a Tacrine (HY-111338) glycoconjugate tethered with acetylated β-Glucose. AChE-IN-9 is also an AChE inhibitor with an IC50 value of 0.4 μM, with lower hepatotoxicity on healthy cells. Tacrine is used in Alzheimer's research[1]. |
| Invitro | Tacrine (HY-111338) is mainly metabolized by CYP 1A2, but its glycoconjugates have shown more affinity towards CYP 3A4 rather than CYP 1A2[1].AChE-IN-9 (compound A-1) (200 μM; 24 h) is non-toxic on HePG2 cell line with 100% cell viability, and shows lower hepatotoxicity than Tacrine (HY-111338) on healthy HepG2 cells[1].AChE-IN-9 (10 μM; 24 h) inhibits AChE activity with inhibition rate of 96.6%[1]. Cell Cytotoxicity Assay[1] Cell Line: |
| Name | AChE-IN-9 |
| Formula | C30H35N5O9 |
| Molar Mass | 609.63 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Kaur Gulati H, et al. Design, Synthesis, biological investigations and molecular interactions of triazole linked tacrine glycoconjugates as Acetylcholinesterase inhibitors with reduced hepatotoxicity. Bioorg Chem. 2022 Jan;118:105479. |